Skip to main content
    K

    Kymera Therapeutics Inc (KYMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $125.85
    -1.72 (-1.35%)

    Market Cap: $10.89B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kymera Therapeutics Inc (KYMR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Kymera Therapeutics are Spyre Therapeutics (SYRE), Krystal Biotech (KRYS) and Cytokinetics (CYTK). By market cap, Kymera Therapeutics ranks 3rd of the 13 companies on this page; Halozyme Therapeutics (HALO) is the largest at $11.43B. The median P/E of the 4 companies with a P/E is 34.1x.

    Peer Comparison

    KYMR's revenue growth of 466.4% is above the peer median of 44.9%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Kymera Therapeutics (KYMR)$10.89BN/A123.2x0.0%N/A466.4%0.00%
    Spyre Therapeutics Inc. (SYRE)$9.88BN/AN/A0.0%N/A0.0%0.00%
    Krystal Biotech Inc (KRYS)$9.05B40.4x18.8x47.9%N/A30.2%0.00%
    Cytokinetics Inc (CYTK)$7.82BN/A65.3x0.0%-66.0%2357.0%0.00%
    Praxis Precision Medicines Inc (PRAX)$9.17BN/AN/A0.0%N/A1349.0%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Rhythm Pharmaceuticals Inc (RYTM)$7.97BN/A26.4x-69.0%-98.6%79.6%0.00%
    Summit Therapeutics PLC (SMMT)$11.32BN/AN/A0.0%N/A-100.0%0.00%
    Apogee Therapeutics, Inc. Common Stock (APGE)$10.22BN/AN/A0.0%N/A0.0%0.00%
    Halozyme Therapeutics Inc (HALO)$11.43B17.8x6.1x26.9%15.8%39.2%0.00%
    Madrigal Pharmaceuticals Inc (MDGL)$9.93BN/A8.7x-10.9%-12.7%50.1%0.00%
    Mirum Pharmaceuticals Inc (MIRM)$6.14BN/A8.9x-134.7%-133.6%39.6%0.00%
    Peer median$9.46B34.1x13.4x0.0%-39.4%44.9%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Kymera Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Spyre Therapeutics Inc. (SYRE)
    Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by...
    SYRE competitors
    Krystal Biotech Inc (KRYS)
    Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United...
    KRYS competitors
    Cytokinetics Inc (CYTK)
    Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering...
    CYTK competitors
    Praxis Precision Medicines Inc (PRAX)
    Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal...
    PRAX competitors
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Rhythm Pharmaceuticals Inc (RYTM)
    Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment...
    RYTM competitors
    Summit Therapeutics PLC (SMMT)
    Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America...
    SMMT competitors
    Apogee Therapeutics, Inc. Common Stock (APGE)
    Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)...
    Halozyme Therapeutics Inc (HALO)
    Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
    HALO competitors
    Madrigal Pharmaceuticals Inc (MDGL)
    Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates...
    MDGL competitors
    Mirum Pharmaceuticals Inc (MIRM)
    Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies...
    MIRM competitors

    Frequently Asked Questions About KYMR

    Who are Kymera Therapeutics' main competitors?

    The companies most similar to Kymera Therapeutics include Spyre Therapeutics (SYRE), Krystal Biotech (KRYS), Cytokinetics (CYTK), Praxis Precision Medicines (PRAX) and TG Therapeutics (TGTX), listed from the closest match.

    Who is Kymera Therapeutics' biggest competitor?

    Halozyme Therapeutics (HALO) is the largest of the similar companies at $11.43B; Spyre Therapeutics (SYRE) is the closest match by business profile, size, sector and industry.

    How does KYMR stock compare with its competitors?

    KYMR's P/S is 123.2x against a peer median of 13.4x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Kymera Therapeutics' competitors pays a higher dividend?

    Kymera Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Kymera Therapeutics bigger than its competitors?

    No. Kymera Therapeutics is 3rd by market cap among the 13 companies on this page; the largest is Halozyme Therapeutics (HALO) at $11.43B.